Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Weber, N., Mollee, P., Augustson, B., Brown, R., Catley, L., Gibson, J., Harrison, S., Ho, P. J., Horvath, N., Jaksic, W., Joshua, D., Quach, H., Roberts, A. W., Spencer, A., Szer, J., Talaulikar, D., To, B., Zannettino, A. and Prince, H. M. (2015) Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 45 4: 371-382. doi:10.1111/imj.12566


Author Weber, N.
Mollee, P.
Augustson, B.
Brown, R.
Catley, L.
Gibson, J.
Harrison, S.
Ho, P. J.
Horvath, N.
Jaksic, W.
Joshua, D.
Quach, H.
Roberts, A. W.
Spencer, A.
Szer, J.
Talaulikar, D.
To, B.
Zannettino, A.
Prince, H. M.
Title Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Journal name Internal Medicine Journal   Check publisher's open access policy
ISSN 1444-0903
1445-5994
Publication date 2015-04
Year available 2015
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1111/imj.12566
Open Access Status DOI
Volume 45
Issue 4
Start page 371
End page 382
Total pages 12
Place of publication Richmond, VIC Australia
Publisher Wiley-Blackwell Publishing Asia
Collection year 2016
Language eng
Formatted abstract
Systemic AL amyloidosis is a plasma cell dyscrasia with a characteristic clinical phenotype caused by multi-organ deposition of an amyloidogenic monoclonal protein. This condition poses a unique management challenge due to the complexity of the clinical presentation and the narrow therapeutic window of available therapies. Improved appreciation of the need for risk stratification, standardised use of sensitive laboratory testing for monitoring disease response, vigilant supportive care and the availability of newer agents with more favourable toxicity profiles have contributed to the improvement in treatment-related mortality and overall survival seen over the past decade. Nonetheless, with respect to the optimal management approach, there is a paucity of high-level clinical evidence due to the rarity of the disease, and enrolment in clinical trials is still the preferred approach where available. This review will summarise the Clinical Practice Guidelines on the Management of Systemic Light Chain (AL) Amyloidosis recently prepared by the Medical Scientific Advisory Group of the Myeloma Foundation of Australia. It is hoped that these guidelines will assist clinicians in better understanding and optimising the management of this difficult disease.
Keyword Amyloidosis
Light Chain Kinase
Plasma cell
Stem cell transplantation
Natriuretic Peptide
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Mater Research Institute-UQ (MRI-UQ)
Official 2016 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 2 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 03 May 2015, 01:47:39 EST by System User on behalf of Medicine - Princess Alexandra Hospital